Forte Biosciences (FBRX) Cash from Investing Activities (QoQ) (2016 - 2025)
Forte Biosciences (FBRX) Cash from Investing Activities (QoQ) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Forte Biosciences | 1.37 Bn | 1.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 200.84% |
| Mar 31, 2024 | 62.50% |
| Dec 31, 2023 | -100.16% |
| Sep 30, 2020 | 99.99% |
| Jun 30, 2020 | -171.84% |
| Mar 31, 2020 | 14,394.38% |
| Dec 31, 2019 | 98.46% |
| Sep 30, 2019 | -1,319.70% |
| Jun 30, 2019 | -106.66% |
| Mar 31, 2019 | 706.48% |
| Dec 31, 2018 | 136.36% |
| Sep 30, 2018 | -361.84% |
| Jun 30, 2018 | 121.69% |
| Mar 31, 2018 | 87.11% |
| Dec 31, 2017 | -474.93% |
| Sep 30, 2017 | 171.08% |
| Jun 30, 2017 | -382.55% |
| Mar 31, 2017 | -44.85% |
| Dec 31, 2016 | 6.28% |
| Sep 30, 2016 | -22.31% |